Responses
Immune cell therapies and immune cell engineering
Original research
Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.